Haematology and Acute Oncology Part One
•
7 likes•440 views
Dr Chris Jenkins, Consultant Haematologist, University Hospital of the North Midlands Dr Andrew Stewart, Consultant Haematologist, The Royal Gwent Hospital
Report
Share
Report
Share
Download to read offline
Recommended
Haematology and Acute Oncology Part Two
Dr Andrew Stewart, Consultant Haematologist, The Royal Gwent Hospital
Dr Chris Jenkins, Consultant Haematologist, University Hospital of the North Midlands
Endocrinology
1) Dr. Claire Higham presented on various endocrinology topics related to oncology, including electrolyte disorders, diabetes complications, immunotherapy toxicities, and bone health issues.
2) The document discussed a case of severe hyponatremia in a patient with small cell lung cancer, likely caused by SIADH. SIADH is the most common cause of hyponatremia in cancer patients.
3) Management of hyponatremia in cancer patients can be challenging given the non-transient nature of SIADH. Tolvaptan may be preferable to other options as it is more effective for cancer-related SIADH.
Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL) is a cancer of the lymphatic system that most often affects children. It is diagnosed based on bone marrow morphology and immunophenotyping. Treatment involves intensive chemotherapy based on pediatric protocols including steroids, vincristine, asparaginase, and methotrexate, along with central nervous system prophylaxis and monitoring of minimal residual disease. Outcomes have improved with targeted therapies for high-risk features and relapses, though relapsed ALL still carries a poor prognosis. Long-term effects of intensive treatment require ongoing monitoring.
Paeds leukemias presentation
The document discusses leukemias, focusing on acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) in children. It defines leukemias as malignant diseases of hematopoietic stem cells that result in abnormal proliferation. ALL is the most common childhood leukemia, accounting for 77% of cases. It presents with nonspecific symptoms and is diagnosed through blood and bone marrow analysis. Treatment involves induction, consolidation, and maintenance phases to eliminate leukemia cells. Prognosis is generally good with a 5-year survival rate around 90%, though survivors often experience chronic health issues. AML is less common in children and presents similarly to ALL. It is classified based on cell morphology and genetics which inform prognosis and treatment
Pediatric renal transplantation
kidney transplantation in pediatrics
ahmed oshiba
pediatric surgery and urology alexandria university
Git j club ap16.
This document provides information on acute pancreatitis including:
- Etiology is often gallstones or alcohol use. Other causes include drugs, genetics, obesity, and diabetes.
- Diagnosis requires abdominal pain consistent with pancreatitis plus serum lipase or amylase 3x upper limit and findings on imaging. CT scan is useful for assessing severity.
- Treatment involves aggressive IV fluids, monitoring for complications, enteral nutrition, and antibiotics only if infection is present. Severe cases may require endoscopic or minimally invasive drainage of pancreatic fluid and necrosis.
- Complications include pancreatic pseudocysts, abscesses, and sterile or infected pancreatic necrosis. Severity is classified based on organ failure
Sarcopenia in Liver Cirrhosis
Sarcopenia develops in liver cirrhosis due to multiple factors:
1) Inadequate dietary intake due to loss of appetite, early satiety, dietary restrictions, and frequent procedures which leads to accelerated starvation and protein loss.
2) Intestinal changes allow bacterial translocation in advanced liver cirrhosis, exposing the body to toxins and increasing inflammation.
3) Hepatic dysfunction results in impaired nutrient processing and increased protein breakdown to produce glucose via gluconeogenesis for energy. This further exacerbates muscle wasting.
Managing sarcopenia is important as it negatively impacts survival and quality of life in cirrhotic patients.
Noon conference 8-16
This document provides an overview of glomerular causes of hematuria including definitions, diagnostic workup, differential diagnoses, and treatment approaches. Key points discussed include:
- Definitions of gross and microscopic hematuria and their clinical significance. Dysmorphic red blood cells and red blood cell casts can indicate glomerular disease but have low sensitivity.
- Diagnostic workup may include complement levels, ANCA, ANA, hepatitis and cryoglobulin serologies to identify underlying causes like ANCA-associated glomerulonephritis, lupus, or hepatitis.
- Biopsy of the kidney has the highest diagnostic yield compared to other organs and should be considered for rapidly progressive or unexplained
Recommended
Haematology and Acute Oncology Part Two
Dr Andrew Stewart, Consultant Haematologist, The Royal Gwent Hospital
Dr Chris Jenkins, Consultant Haematologist, University Hospital of the North Midlands
Endocrinology
1) Dr. Claire Higham presented on various endocrinology topics related to oncology, including electrolyte disorders, diabetes complications, immunotherapy toxicities, and bone health issues.
2) The document discussed a case of severe hyponatremia in a patient with small cell lung cancer, likely caused by SIADH. SIADH is the most common cause of hyponatremia in cancer patients.
3) Management of hyponatremia in cancer patients can be challenging given the non-transient nature of SIADH. Tolvaptan may be preferable to other options as it is more effective for cancer-related SIADH.
Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL) is a cancer of the lymphatic system that most often affects children. It is diagnosed based on bone marrow morphology and immunophenotyping. Treatment involves intensive chemotherapy based on pediatric protocols including steroids, vincristine, asparaginase, and methotrexate, along with central nervous system prophylaxis and monitoring of minimal residual disease. Outcomes have improved with targeted therapies for high-risk features and relapses, though relapsed ALL still carries a poor prognosis. Long-term effects of intensive treatment require ongoing monitoring.
Paeds leukemias presentation
The document discusses leukemias, focusing on acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) in children. It defines leukemias as malignant diseases of hematopoietic stem cells that result in abnormal proliferation. ALL is the most common childhood leukemia, accounting for 77% of cases. It presents with nonspecific symptoms and is diagnosed through blood and bone marrow analysis. Treatment involves induction, consolidation, and maintenance phases to eliminate leukemia cells. Prognosis is generally good with a 5-year survival rate around 90%, though survivors often experience chronic health issues. AML is less common in children and presents similarly to ALL. It is classified based on cell morphology and genetics which inform prognosis and treatment
Pediatric renal transplantation
kidney transplantation in pediatrics
ahmed oshiba
pediatric surgery and urology alexandria university
Git j club ap16.
This document provides information on acute pancreatitis including:
- Etiology is often gallstones or alcohol use. Other causes include drugs, genetics, obesity, and diabetes.
- Diagnosis requires abdominal pain consistent with pancreatitis plus serum lipase or amylase 3x upper limit and findings on imaging. CT scan is useful for assessing severity.
- Treatment involves aggressive IV fluids, monitoring for complications, enteral nutrition, and antibiotics only if infection is present. Severe cases may require endoscopic or minimally invasive drainage of pancreatic fluid and necrosis.
- Complications include pancreatic pseudocysts, abscesses, and sterile or infected pancreatic necrosis. Severity is classified based on organ failure
Sarcopenia in Liver Cirrhosis
Sarcopenia develops in liver cirrhosis due to multiple factors:
1) Inadequate dietary intake due to loss of appetite, early satiety, dietary restrictions, and frequent procedures which leads to accelerated starvation and protein loss.
2) Intestinal changes allow bacterial translocation in advanced liver cirrhosis, exposing the body to toxins and increasing inflammation.
3) Hepatic dysfunction results in impaired nutrient processing and increased protein breakdown to produce glucose via gluconeogenesis for energy. This further exacerbates muscle wasting.
Managing sarcopenia is important as it negatively impacts survival and quality of life in cirrhotic patients.
Noon conference 8-16
This document provides an overview of glomerular causes of hematuria including definitions, diagnostic workup, differential diagnoses, and treatment approaches. Key points discussed include:
- Definitions of gross and microscopic hematuria and their clinical significance. Dysmorphic red blood cells and red blood cell casts can indicate glomerular disease but have low sensitivity.
- Diagnostic workup may include complement levels, ANCA, ANA, hepatitis and cryoglobulin serologies to identify underlying causes like ANCA-associated glomerulonephritis, lupus, or hepatitis.
- Biopsy of the kidney has the highest diagnostic yield compared to other organs and should be considered for rapidly progressive or unexplained
2014 crohns colitis assoc concord hospital forum psc rupert leong
This document discusses primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts. It provides details on the epidemiology, associated conditions, diagnosis, and treatment of PSC. Highlights include that PSC often co-occurs with inflammatory bowel disease, diagnosis involves cholangiography to detect bile duct abnormalities, and treatments like ursodeoxycholic acid and liver transplantation are discussed. The document also describes local data on PSC patients and initiatives to support research and patients through a new Australian Bowel Foundation.
Rheumatic Diseases | Rheumatoid Arthritis
This document provides an overview of rheumatoid arthritis (RA) and evaluating patients with rheumatic diseases. It discusses evaluating joint swelling based on distribution, acute vs chronic symptoms, and evidence of systemic inflammation. Common tests in rheumatology like joint aspiration and antibodies are also outlined. RA is introduced as a chronic inflammatory disease affecting the synovium. Diagnostic criteria, manifestations, associated syndromes, laboratory findings, and treatment options for RA are summarized. Complications of RA like atlantoaxial subluxation are also mentioned.
inflammatory bowel disease in elderly
This document discusses inflammatory bowel disease (IBD) in elderly patients. It notes that up to 30% of the IBD population is aged 60 or older, and half of those were diagnosed after age 60. The pathogenesis of late-onset IBD is unclear but may involve immunosenescence and changes in the gut microbiome. Elderly IBD patients often experience delays in diagnosis due to atypical presentations. Treatment options need to consider safety risks in elderly patients from comorbidities and polypharmacy. While guidelines do not differ for elderly patients, treatment must balance efficacy against risks of side effects on an individual basis.
Benign tumour of liver hemangioma
Benign tumour of liver: Hemangioma. brief discussion on benign tumors of liver . Hemangioma is the most common benign tumor of liver.
Onconephrology shield the kidney while fighting cancer , dr ayman seddik
This document discusses kidney diseases that can occur in patients with cancer or undergoing cancer treatment. It begins by defining onconephrology as the field of nephrology dealing with kidney complications of cancer. Common reasons a nephrologist may be consulted include kidney diseases that predate or develop during cancer, new glomerular diseases, obstructive nephropathy, tubular damage, thrombotic microangiopathy, radiation nephropathy, tumor invasion of the kidney, tumor lysis syndrome, and electrolyte disorders. Kidney complications discussed in more depth include acute kidney injury, cancer-associated glomerulopathy, chemotherapy-associated tubulointerstitial nephritis, hypercalcemia of
Onconephrology
onco-nephrology this missed part of our spectrum of care to very specific group of patients>>>cancer patients
this is introduction to types of chemotherapy, causes and how to manage AKI caused by these drugs
Cardio oncology
This document discusses cardiotoxicity from chemotherapy, specifically anthracyclines, and its management. It provides a case study of a breast cancer patient with pre-existing cardiac disease receiving chemotherapy. Key points discussed include:
1. Anthracyclines are effective chemotherapy but can cause dose-dependent cardiotoxicity and heart failure.
2. Various modalities can help detect cardiotoxicity early, including echocardiography, tissue Doppler imaging, and cardiac biomarkers.
3. While chemotherapy may cause cardiac damage, optimal heart failure therapy can significantly improve cardiac function for many patients.
4. Careful consideration of cardiac risk factors and function is important when choosing chemotherapy regimens and monitoring for toxicity
Cardio-Oncology & Advanced Heart Failure Therapies
This document summarizes a presentation about cardio-oncology at the Minneapolis Heart Institute. It discusses the growing field of cardio-oncology due to improved cancer survival rates and increased risk of cardiovascular side effects from newer cancer therapies. The presentation outlines several chemotherapy agents known to cause cardiotoxicity, as well as risk factors. It then describes the cardio-oncology clinic at MHI, which has expanded to include multiple physicians, nurse practitioners, and a nurse coordinator to closely monitor patients receiving chemotherapy. The clinic aims to prevent and quickly treat any cardiotoxicity through protocols for imaging, medication management, and follow-up care. Statistics on current clinic patients are provided, as well as considerations for referral. Future research initiatives in prevention and
Primary Biliary Cholangitis
This document summarizes key aspects of primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis. It discusses the epidemiology, risk factors, natural history, presentation, diagnosis and management of PBC. If left untreated, PBC progresses through several clinical phases over many years, eventually leading to liver failure and death in some patients. Prognosis is generally better in asymptomatic patients than in those with symptoms.
VTE and Cancer Healthcare Professional Education
Cancer patients are at increased risk of developing blood clots (venous thromboembolism or VTE) due to factors such as tumour infiltration of blood vessels, immobility, and cancer treatments. VTE is a leading cause of death in cancer patients and the risk is highest in the first months after diagnosis. Guidelines recommend thromboprophylaxis for hospitalized cancer patients without bleeding risk, but evidence for routine outpatient prophylaxis is limited to certain high risk groups. Risk assessment tools can help identify those at highest risk who may benefit most from prophylaxis.
Antitubercular agents in TB patients with Chronic Liver disease (CLD)
Antitubercular agents in TB patients with Chronic Liver disease (CLD). Brief review on how to initiate and maintan ATT IN CLD patients.
Venous thromboembolism in cancer.presentation
Venous thromboembolism (VTE) is common in patients with malignancy and carries a high risk of morbidity and mortality. Approximately 15% of cancer patients will develop symptomatic VTE, and VTE is the second leading cause of death among hospitalized cancer patients. The risk of VTE is increased by certain tumor types, advanced stage, chemotherapy, and surgery. The pathophysiology involves stasis, endothelial injury, and a hypercoagulable state induced by tumor-derived procoagulants and cytokines. Prevention includes pharmacological prophylaxis with low molecular weight heparin for high-risk patients. Treatment of VTE involves initial parenteral anticoagulation followed by long-term therapy typically
TIPS in Ascites
The document discusses tips for managing ascites, including performing large volume paracentesis with albumin and continuing diuretics if renal sodium excretion is over 30 mmol/day. It also discusses using non-selective beta-blockers and transjugular intrahepatic portosystemic shunts (TIPS) to treat refractory ascites, noting that TIPS significantly reduces hepatic encephalopathy compared to large volume paracentesis alone. TIPS is an effective option for controlling ascites but carries a higher risk of hepatic encephalopathy compared to large volume paracentesis.
HCV in CKD
This document discusses treatment of hepatitis C in patients with chronic kidney disease. It begins by establishing the association between HCV infection and CKD, noting that HCV can cause renal impairment and progression of kidney disease through various mechanisms. It then reviews outcomes in this population such as increased prevalence of CKD, faster progression to ESRD, higher mortality rates, and poorer outcomes after renal transplant compared to those without HCV infection. The document next evaluates earlier treatment options with interferon-based regimens, which had low efficacy and significant side effects. It then discusses approval and study of newer direct-acting antiviral regimens, finding improved efficacy and safety particularly with sofosbuvir and glecaprevir/pibrentasvir
Q&A with Expert About Blood Clots & Cancer
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Signs and symptoms of blood clots, also known as venous thrombosis
● What types of treatments are available
● Why people living with cancer should be aware of the dangers of blood clots and what to do if they occur.
View the video: https://youtu.be/PbZQCHRhoOQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Inotuzumab ozogamicin (BESPONSA)
Inotuzumab ozogamicin is an antibody-drug conjugate being studied for the treatment of acute lymphoblastic leukemia (ALL) in adults. The INO-VATE ALL study compared inotuzumab ozogamicin to standard chemotherapy for adults with relapsed or refractory ALL. The primary objectives were to demonstrate higher rates of complete remission and longer overall survival with inotuzumab ozogamicin. Complete remission, safety, and overall survival were evaluated. If shown to be effective, inotuzumab ozogamicin could provide a new treatment option for adults with relapsed/refractory ALL.
Cardiotoxicity. risk assessment and early diagnosis.
This document discusses cardiotoxicity risks from cancer treatment and the importance of early diagnosis. It covers:
- Risk factors for cardiotoxicity including certain drugs, doses, age, and heart conditions.
- Diagnostic criteria for heart failure and left ventricular dysfunction as definitions evolve.
- Tools for diagnosing cardiac issues like echocardiograms, MUGA scans, NMR, and CT. Troponin and echos may help early detection.
- The need for local protocols and multidisciplinary teams to manage risks and allow for early intervention given long-term cardiac risks for cancer survivors.
Autoimmune hepatitis rajesh
This document provides information on autoimmune hepatitis, including:
- It is a chronic hepatitis of unknown etiology that can progress to cirrhosis. It is characterized by the presence of autoimmune antibodies and evidence of hepatitis.
- The two main types are type 1, associated with ANA/SMA positivity, and type 2, associated with LKM1 positivity.
- Treatment involves immunosuppressive drugs like prednisone, either alone or in combination with azathioprine. The goal is to induce and maintain remission.
- Remission is defined as resolution of symptoms and normalization of liver tests and histology. Treatment is then tapered slowly to maintain remission.
Acute on chronic liver failure
This document discusses acute-on-chronic liver failure (ACLF), comparing existing definitions from APASL, EASL/CLIF, and NASCELD. It notes that while not consistent, the definitions lay groundwork for future research. The APASL definition focuses on an acute hepatic insult leading to liver failure within 4 weeks in patients with chronic liver disease/cirrhosis. EASL/CLIF and NASCELD have broader definitions not requiring liver failure, instead focusing on extrahepatic organ failures. The document also discusses the "golden window" period for treatment, reversibility of ACLF, grading systems for prognosis, and the APASL ACLF research consortium database.
Role of tips in liver disease
The document provides information on the role of transjugular intrahepatic portosystemic shunt (TIPS) in treating liver diseases. It discusses how TIPS works to create a channel between the hepatic vein and portal vein using a metal stent to reduce portal pressure. The document outlines guidelines for using TIPS to treat variceal hemorrhaging and describes factors like MELD scores that can help identify high-risk patients who may benefit from early TIPS placement. It also reviews the history of TIPS development and provides details on how to perform the TIPS procedure and assess outcomes.
Childhood leukemia long vr
1. Acute leukemia is the most common childhood cancer, with acute lymphoblastic leukemia (ALL) being the most common type. ALL accounts for about 80% of cases of childhood acute leukemia.
2. Diagnosis involves blood tests, bone marrow examination, immunophenotyping, cytogenetics and lumbar puncture. Bone marrow shows hypercellularity with over 25% blasts.
3. Treatment involves risk stratification based on factors like age, white blood cell count, immunophenotype and cytogenetics. Supportive care is also important to manage complications like infections. Prognosis is generally good but depends on risk factors, with younger age and lower white blood cell count indicating a more
Leukaemia for bds
Leukaemia is a group of malignant blood disorders affecting the bone marrow and blood-forming tissues. There are four main types classified by whether the affected cells are lymphoid or myeloid, and whether the disease course is acute or chronic. Acute leukemias involve immature blast cells and a rapid progression, while chronic leukemias involve more mature cells and a slower course. The document defines each type and discusses their signs, symptoms, diagnosis, prognostic factors and treatment approaches.
More Related Content
What's hot
2014 crohns colitis assoc concord hospital forum psc rupert leong
This document discusses primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts. It provides details on the epidemiology, associated conditions, diagnosis, and treatment of PSC. Highlights include that PSC often co-occurs with inflammatory bowel disease, diagnosis involves cholangiography to detect bile duct abnormalities, and treatments like ursodeoxycholic acid and liver transplantation are discussed. The document also describes local data on PSC patients and initiatives to support research and patients through a new Australian Bowel Foundation.
Rheumatic Diseases | Rheumatoid Arthritis
This document provides an overview of rheumatoid arthritis (RA) and evaluating patients with rheumatic diseases. It discusses evaluating joint swelling based on distribution, acute vs chronic symptoms, and evidence of systemic inflammation. Common tests in rheumatology like joint aspiration and antibodies are also outlined. RA is introduced as a chronic inflammatory disease affecting the synovium. Diagnostic criteria, manifestations, associated syndromes, laboratory findings, and treatment options for RA are summarized. Complications of RA like atlantoaxial subluxation are also mentioned.
inflammatory bowel disease in elderly
This document discusses inflammatory bowel disease (IBD) in elderly patients. It notes that up to 30% of the IBD population is aged 60 or older, and half of those were diagnosed after age 60. The pathogenesis of late-onset IBD is unclear but may involve immunosenescence and changes in the gut microbiome. Elderly IBD patients often experience delays in diagnosis due to atypical presentations. Treatment options need to consider safety risks in elderly patients from comorbidities and polypharmacy. While guidelines do not differ for elderly patients, treatment must balance efficacy against risks of side effects on an individual basis.
Benign tumour of liver hemangioma
Benign tumour of liver: Hemangioma. brief discussion on benign tumors of liver . Hemangioma is the most common benign tumor of liver.
Onconephrology shield the kidney while fighting cancer , dr ayman seddik
This document discusses kidney diseases that can occur in patients with cancer or undergoing cancer treatment. It begins by defining onconephrology as the field of nephrology dealing with kidney complications of cancer. Common reasons a nephrologist may be consulted include kidney diseases that predate or develop during cancer, new glomerular diseases, obstructive nephropathy, tubular damage, thrombotic microangiopathy, radiation nephropathy, tumor invasion of the kidney, tumor lysis syndrome, and electrolyte disorders. Kidney complications discussed in more depth include acute kidney injury, cancer-associated glomerulopathy, chemotherapy-associated tubulointerstitial nephritis, hypercalcemia of
Onconephrology
onco-nephrology this missed part of our spectrum of care to very specific group of patients>>>cancer patients
this is introduction to types of chemotherapy, causes and how to manage AKI caused by these drugs
Cardio oncology
This document discusses cardiotoxicity from chemotherapy, specifically anthracyclines, and its management. It provides a case study of a breast cancer patient with pre-existing cardiac disease receiving chemotherapy. Key points discussed include:
1. Anthracyclines are effective chemotherapy but can cause dose-dependent cardiotoxicity and heart failure.
2. Various modalities can help detect cardiotoxicity early, including echocardiography, tissue Doppler imaging, and cardiac biomarkers.
3. While chemotherapy may cause cardiac damage, optimal heart failure therapy can significantly improve cardiac function for many patients.
4. Careful consideration of cardiac risk factors and function is important when choosing chemotherapy regimens and monitoring for toxicity
Cardio-Oncology & Advanced Heart Failure Therapies
This document summarizes a presentation about cardio-oncology at the Minneapolis Heart Institute. It discusses the growing field of cardio-oncology due to improved cancer survival rates and increased risk of cardiovascular side effects from newer cancer therapies. The presentation outlines several chemotherapy agents known to cause cardiotoxicity, as well as risk factors. It then describes the cardio-oncology clinic at MHI, which has expanded to include multiple physicians, nurse practitioners, and a nurse coordinator to closely monitor patients receiving chemotherapy. The clinic aims to prevent and quickly treat any cardiotoxicity through protocols for imaging, medication management, and follow-up care. Statistics on current clinic patients are provided, as well as considerations for referral. Future research initiatives in prevention and
Primary Biliary Cholangitis
This document summarizes key aspects of primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis. It discusses the epidemiology, risk factors, natural history, presentation, diagnosis and management of PBC. If left untreated, PBC progresses through several clinical phases over many years, eventually leading to liver failure and death in some patients. Prognosis is generally better in asymptomatic patients than in those with symptoms.
VTE and Cancer Healthcare Professional Education
Cancer patients are at increased risk of developing blood clots (venous thromboembolism or VTE) due to factors such as tumour infiltration of blood vessels, immobility, and cancer treatments. VTE is a leading cause of death in cancer patients and the risk is highest in the first months after diagnosis. Guidelines recommend thromboprophylaxis for hospitalized cancer patients without bleeding risk, but evidence for routine outpatient prophylaxis is limited to certain high risk groups. Risk assessment tools can help identify those at highest risk who may benefit most from prophylaxis.
Antitubercular agents in TB patients with Chronic Liver disease (CLD)
Antitubercular agents in TB patients with Chronic Liver disease (CLD). Brief review on how to initiate and maintan ATT IN CLD patients.
Venous thromboembolism in cancer.presentation
Venous thromboembolism (VTE) is common in patients with malignancy and carries a high risk of morbidity and mortality. Approximately 15% of cancer patients will develop symptomatic VTE, and VTE is the second leading cause of death among hospitalized cancer patients. The risk of VTE is increased by certain tumor types, advanced stage, chemotherapy, and surgery. The pathophysiology involves stasis, endothelial injury, and a hypercoagulable state induced by tumor-derived procoagulants and cytokines. Prevention includes pharmacological prophylaxis with low molecular weight heparin for high-risk patients. Treatment of VTE involves initial parenteral anticoagulation followed by long-term therapy typically
TIPS in Ascites
The document discusses tips for managing ascites, including performing large volume paracentesis with albumin and continuing diuretics if renal sodium excretion is over 30 mmol/day. It also discusses using non-selective beta-blockers and transjugular intrahepatic portosystemic shunts (TIPS) to treat refractory ascites, noting that TIPS significantly reduces hepatic encephalopathy compared to large volume paracentesis alone. TIPS is an effective option for controlling ascites but carries a higher risk of hepatic encephalopathy compared to large volume paracentesis.
HCV in CKD
This document discusses treatment of hepatitis C in patients with chronic kidney disease. It begins by establishing the association between HCV infection and CKD, noting that HCV can cause renal impairment and progression of kidney disease through various mechanisms. It then reviews outcomes in this population such as increased prevalence of CKD, faster progression to ESRD, higher mortality rates, and poorer outcomes after renal transplant compared to those without HCV infection. The document next evaluates earlier treatment options with interferon-based regimens, which had low efficacy and significant side effects. It then discusses approval and study of newer direct-acting antiviral regimens, finding improved efficacy and safety particularly with sofosbuvir and glecaprevir/pibrentasvir
Q&A with Expert About Blood Clots & Cancer
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Signs and symptoms of blood clots, also known as venous thrombosis
● What types of treatments are available
● Why people living with cancer should be aware of the dangers of blood clots and what to do if they occur.
View the video: https://youtu.be/PbZQCHRhoOQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Inotuzumab ozogamicin (BESPONSA)
Inotuzumab ozogamicin is an antibody-drug conjugate being studied for the treatment of acute lymphoblastic leukemia (ALL) in adults. The INO-VATE ALL study compared inotuzumab ozogamicin to standard chemotherapy for adults with relapsed or refractory ALL. The primary objectives were to demonstrate higher rates of complete remission and longer overall survival with inotuzumab ozogamicin. Complete remission, safety, and overall survival were evaluated. If shown to be effective, inotuzumab ozogamicin could provide a new treatment option for adults with relapsed/refractory ALL.
Cardiotoxicity. risk assessment and early diagnosis.
This document discusses cardiotoxicity risks from cancer treatment and the importance of early diagnosis. It covers:
- Risk factors for cardiotoxicity including certain drugs, doses, age, and heart conditions.
- Diagnostic criteria for heart failure and left ventricular dysfunction as definitions evolve.
- Tools for diagnosing cardiac issues like echocardiograms, MUGA scans, NMR, and CT. Troponin and echos may help early detection.
- The need for local protocols and multidisciplinary teams to manage risks and allow for early intervention given long-term cardiac risks for cancer survivors.
Autoimmune hepatitis rajesh
This document provides information on autoimmune hepatitis, including:
- It is a chronic hepatitis of unknown etiology that can progress to cirrhosis. It is characterized by the presence of autoimmune antibodies and evidence of hepatitis.
- The two main types are type 1, associated with ANA/SMA positivity, and type 2, associated with LKM1 positivity.
- Treatment involves immunosuppressive drugs like prednisone, either alone or in combination with azathioprine. The goal is to induce and maintain remission.
- Remission is defined as resolution of symptoms and normalization of liver tests and histology. Treatment is then tapered slowly to maintain remission.
Acute on chronic liver failure
This document discusses acute-on-chronic liver failure (ACLF), comparing existing definitions from APASL, EASL/CLIF, and NASCELD. It notes that while not consistent, the definitions lay groundwork for future research. The APASL definition focuses on an acute hepatic insult leading to liver failure within 4 weeks in patients with chronic liver disease/cirrhosis. EASL/CLIF and NASCELD have broader definitions not requiring liver failure, instead focusing on extrahepatic organ failures. The document also discusses the "golden window" period for treatment, reversibility of ACLF, grading systems for prognosis, and the APASL ACLF research consortium database.
Role of tips in liver disease
The document provides information on the role of transjugular intrahepatic portosystemic shunt (TIPS) in treating liver diseases. It discusses how TIPS works to create a channel between the hepatic vein and portal vein using a metal stent to reduce portal pressure. The document outlines guidelines for using TIPS to treat variceal hemorrhaging and describes factors like MELD scores that can help identify high-risk patients who may benefit from early TIPS placement. It also reviews the history of TIPS development and provides details on how to perform the TIPS procedure and assess outcomes.
What's hot (20)
2014 crohns colitis assoc concord hospital forum psc rupert leong
2014 crohns colitis assoc concord hospital forum psc rupert leong
Onconephrology shield the kidney while fighting cancer , dr ayman seddik
Onconephrology shield the kidney while fighting cancer , dr ayman seddik
Cardio-Oncology & Advanced Heart Failure Therapies
Cardio-Oncology & Advanced Heart Failure Therapies
Antitubercular agents in TB patients with Chronic Liver disease (CLD)
Antitubercular agents in TB patients with Chronic Liver disease (CLD)
Cardiotoxicity. risk assessment and early diagnosis.
Cardiotoxicity. risk assessment and early diagnosis.
Similar to Haematology and Acute Oncology Part One
Childhood leukemia long vr
1. Acute leukemia is the most common childhood cancer, with acute lymphoblastic leukemia (ALL) being the most common type. ALL accounts for about 80% of cases of childhood acute leukemia.
2. Diagnosis involves blood tests, bone marrow examination, immunophenotyping, cytogenetics and lumbar puncture. Bone marrow shows hypercellularity with over 25% blasts.
3. Treatment involves risk stratification based on factors like age, white blood cell count, immunophenotype and cytogenetics. Supportive care is also important to manage complications like infections. Prognosis is generally good but depends on risk factors, with younger age and lower white blood cell count indicating a more
Leukaemia for bds
Leukaemia is a group of malignant blood disorders affecting the bone marrow and blood-forming tissues. There are four main types classified by whether the affected cells are lymphoid or myeloid, and whether the disease course is acute or chronic. Acute leukemias involve immature blast cells and a rapid progression, while chronic leukemias involve more mature cells and a slower course. The document defines each type and discusses their signs, symptoms, diagnosis, prognostic factors and treatment approaches.
leukemia.pptx
The document discusses the classification and treatment of various types of leukemia. It begins by defining leukemia as the neoplastic proliferation of white blood cells. Leukemias are classified as either lymphoid or myeloid and as either acute or chronic depending on the affected cell type and disease progression. The four major types are described as acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia and chronic myelogenous leukemia. Treatment options are discussed including chemotherapy regimens, bone marrow transplantation, supportive care and goals of treatment.
Lymphoma
This document discusses lymphomas, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. It covers the classification, pathogenesis, clinical features, investigations, and treatment of these conditions. Key points include: lymphomas are malignant tumors of lymphoreticular tissues, Hodgkin's lymphoma is characterized by the presence of Reed-Sternberg cells, classifications include Rye and WHO systems, clinical features depend on location and include enlarged lymph nodes and systemic symptoms, investigations involve imaging, biopsies and blood tests, and treatment involves chemotherapy, radiation therapy, bone marrow transplants or supportive care.
Haematological malignancies
The document discusses various types of haematological malignancies including leukaemias and lymphomas. It provides details on:
1) Classification of leukaemias into acute and chronic forms based on onset and progression, and into lymphoblastic or myeloid types based on cell of origin. Acute leukaemias are more aggressive while chronic forms are less chemosensitive.
2) Presentation, investigations and management of specific leukaemias - acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) and chronic lymphoblastic leukaemia (CLL).
3) Hodgkin's lymphoma
Presentation on leukaemia
This document provides an overview of leukemia, including its definition, types, causes, symptoms, diagnosis, treatment, and nursing management. It discusses the main types of leukemia - acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. For each type, it covers clinical manifestations, diagnostic evaluation, medical management options like chemotherapy and stem cell transplantation, and associated nursing care. The document also reviews the TNM staging system and mentions a research study on imatinib therapy for chronic myeloid leukemia.
leukemiainchildren-171030175121.pptx By Dr Saptarshi Bhattacharyya Senior Co...
Leukemias are the most common cancers in children, with acute lymphoblastic leukemia (ALL) accounting for 73% of cases and acute myeloid leukemia (AML) accounting for 18% of cases. ALL peaks between ages 2-5 years and accounts for 25-30% of all childhood cancers. It is classified and treated based on cellular morphology, immunophenotyping, cytogenetics, and response to induction therapy. Treatment involves induction, consolidation, continuation phases using chemotherapy and sometimes stem cell transplantation or newer targeted drugs. Risk stratification guides intensity of therapy needed. Relapse occurs in 20% despite current treatments.
LEUKEMIC DISEASES AND THE EYE.pptx. This talks about the ocular manifestation...
This document provides an overview of leukemic diseases and their ocular manifestations. It discusses the different types of leukemia including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. It covers the pathogenesis, classification, signs and symptoms, diagnostic testing including blood counts, bone marrow examination, and cytochemical staining. It also describes the various ocular changes that can occur due to anemia, thrombocytopenia, hyperviscosity, thrombosis, infiltration of tissues, and metabolic abnormalities associated with leukemias.
Acute lymphoblastic leukemia dr narmada
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. It is characterized by the overproduction of immature white blood cells called lymphoblasts. The disease is classified based on immunophenotyping and cytogenetics. Prognostic factors include age, white blood cell count, cytogenetics, and immunophenotype. Diagnosis involves examination of peripheral blood, bone marrow aspirate, immunophenotyping, cytogenetics, and molecular testing. Treatment and monitoring of minimal residual disease is important. Genetic conditions and environmental exposures can predispose children to developing ALL.
ACUTE LEUKAEMIA Anika.ppt
Acute lymphoblastic leukaemia (ALL) is a cancer of the lymphoid cells characterized by the overproduction of immature white blood cells. It most commonly affects children aged 3-7 years but can also affect adults over 40. The cause is unknown but genetic factors and certain infections/chemical exposures are associated with increased risk. Symptoms include fatigue, bleeding, and infections due to bone marrow failure and organ infiltration by cancerous cells. Diagnosis involves blood and bone marrow tests showing excess immature white blood cells. Treatment aims to induce remission through chemotherapy with stem cell transplant offering a potential cure in some cases. Prognosis depends on factors like age, white blood cell count, and ability to achieve
myeloid malignancy overview
This document provides an overview of the myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). It describes key characteristics of each condition, such as increased mature cells in MPNs, decreased blood cells in MDS, and presence of immature cells in AML. Diagnostic criteria and classification systems for AML, including the 2008 WHO classification, are reviewed. Risk stratification in AML and standard treatment approaches are also summarized. Two clinical cases are then presented and discussed in detail.
Leukemia in Children
Leukemias are the most common cancers in children, with acute lymphoblastic leukemia (ALL) accounting for 73% of cases and acute myeloid leukemia (AML) accounting for 18% of cases. ALL peaks between ages 2-5 years and accounts for 25-30% of all childhood cancers. Treatment involves induction, consolidation/intensification, and continuation phases using chemotherapy protocols over 2-3 years. Supportive care and risk stratification are important for managing treatment and prognosis.
leukemia.pdf
BIBLIOGRAPHY:
Datta Parul, Textbook of Pediatric Nursing, edition 4, The medical sciences publishers, 4838/24 Ansari road, Daryaganj, New Delhi, 110002, India
INTRODUCTION
Leukemia is the most common type of childhood malignancy.
It is characterized by persistent and uncontrolled production immature and abnormal WBCs.
It is a disease of abnormal proliferation and maturation of bone marrow which interferes with the production of normal RBCs, WBCs and platelets.
Leukemia is defined as uncontrolled neoplastic proliferation of leukocyte precursors.
According to National Cancer Institute,
Leukemia is defined as a cancer that starts in blood-forming tissue, such as the bone marrow, and causes large number of abnormal cells to be produced and enter the bloodstream.
95-98% of childhood leukemia are acute type.
70-75% of acute lymphocytic leukemia.
common malignancy of children less than 15 years.
peak incidence is four years of age.
males are more affected than females.
twice more common in white then black in children.
The exact cause is unknown.
viruses like HPV ,Epstein Barr virus ,human T cell lymphoma leukemia virus (HTLV).
Radiations
exposure to chemicals and drugs like benzene and Dilantin
familial predisposition
chromosomal abnormalities like Down syndrome
Genetic like Fanconi's anemia ,bloom syndrome
ACUTE LYMPHOCYTIC LEUKEMIA
Primary disorder of bone marrow in which normal bone marrow elements are replaced by immature or undifferentiated blast cells.
develop when lymphoid cell line is affected.
characterized by anemia, thrombocytopenia, neutropenia, especially granulocytopenia.
the incidence rate is one in 2000 live birth.
the peak age of onset is 3 to 7 years and males are more affected than females
According to French American British classification on the basis of cell morphology it is classified as
L1
L2
L3
According to type of cell it is classified as
T cell
B cell
Pre-B cell
Null cell
T cell
10 to 15% ,high risk ,seen in older children especially males ,featured as mediastinal mass ,hepatosplenomegaly ,high WBC count ,CNS involvement and has poor prognosis.
B cell
1 to 2% children ,aggressive form ,poor prognosis and high-risk type.
Pre-B cell
Good prognosis and respond well to therapy.
Null cell
No cellular surface markers (80% ).
Great imitator, with vague and varied signs and symptoms, resembling almost any disease.
Peripheral blood examination which shows decrease hemoglobin, RBC, hematocrit and platelet count
bone marrow analysis in which large number of lymphoblasts and lymphocytes with hypercellular visible.
chest X-ray
CSF
Chemotherapy
radiation therapy
bone marrow transplantation
supportive and symptomatic management
Chemotherapy
Remission induction chemotherapy
Vincristine, Prednisolone, Asparaginase and Adriamycin are given for 4-6 weeks.
maintenance therapy or systemic continuation
6 MP (Mercaptopurine) and MTX (Methotrexate) are given for 2.5-3 years.
late intensification or THERAPY
Multiple Myeloma
This document provides information about multiple myeloma, including key statistics, risk factors, symptoms, diagnosis, and tests. It summarizes findings from a retrospective analysis of over 1,000 multiple myeloma patients at the Mayo Clinic from 1985 to 1988. The analysis found that the median age at diagnosis was 66 years old, common symptoms at presentation included anemia (73% of patients), bone pain (60% of patients), and renal disease (20% of patients had elevated creatinine). The median survival time was 33 months and did not improve from 1985 to 1988.
leukemia
Cancer is a disease where abnormal cells divide uncontrollably and invade other tissues. There are over 100 types of cancer. Leukemia is a cancer of the blood cells that starts in the bone marrow. There are different types of leukemia such as acute lymphocytic, acute myelocytic, chronic lymphocytic, and chronic myelocytic leukemia. During leukemia, infections, anemia, easy bruising, weight loss, and other symptoms can occur as the extra leukemia cells crowd out healthy blood cells. Both men, women, and children of any age can be susceptible to various cancers. Risk factors for leukemia include radiation, smoking, certain chemicals, viruses, and family history. Diagnosing leukemia involves medical history,
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptx
Brief introduction and description of Common Childhood cancer - Leukaemia , for undergraduate teaching
leukemiainchildren-171030175121 (1).pptx
Leukemias are the most common cancers affecting children, with acute lymphoblastic leukemia (ALL) accounting for 73% of cases and acute myeloid leukemia (AML) accounting for 18% of cases. ALL incidence peaks between ages 2-5 years and accounts for 25-30% of all childhood cancers. Treatment involves induction, consolidation/intensification, and continuation phases using chemotherapy, immunotherapy, stem cell transplantation, and supportive care. The goal is to achieve remission and prevent relapse through risk stratification and tailored therapy.
Lymphoma by Sunil Kumar Daha (Hodgkins and Non-Hodgkins)
Please find the power point onLymphoma . I tried to present it on understandable way and all the contents are reviewed by experts and from very reliable references. Thank you
Leukemia , causes, clinical features, raktarbud
Leukemia is a cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells. There are several types classified by how quickly the disease develops (acute or chronic) and the affected blood cell type (lymphoid or myeloid). Common types include acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. Treatment involves chemotherapy, radiation therapy, or stem cell transplantation and varies depending on the leukemia type and stage.
Similar to Haematology and Acute Oncology Part One (20)
leukemiainchildren-171030175121.pptx By Dr Saptarshi Bhattacharyya Senior Co...
leukemiainchildren-171030175121.pptx By Dr Saptarshi Bhattacharyya Senior Co...
LEUKEMIC DISEASES AND THE EYE.pptx. This talks about the ocular manifestation...
LEUKEMIC DISEASES AND THE EYE.pptx. This talks about the ocular manifestation...
leukemia in children with difference btw all and bll
leukemia in children with difference btw all and bll
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptx
Dr. Vannala Raju UG Class-Childhood Leukaemias.pptx
Lymphoma by Sunil Kumar Daha (Hodgkins and Non-Hodgkins)
Lymphoma by Sunil Kumar Daha (Hodgkins and Non-Hodgkins)
More from RecoveryPackage
Top tips for new AO services
The document provides top tips for setting up or expanding acute oncology services based on workshops and discussions. It includes tips in areas such as collecting baseline data, engaging stakeholders, identifying needed staff and skills, establishing practical resources like referral processes and education programs, and providing 7 day services. Contact information is also included for individuals working at services that may provide useful examples.
#7 Extending Simulation to the Specialists: Acute Oncology Simulation
This document discusses piloting an acute oncology simulation for medical students on managing neutropenic sepsis. 33 of 35 students attended the voluntary simulation. Student feedback found the simulation an effective way to learn about neutropenic sepsis and their confidence in managing it increased. The simulation will now be formally adopted in acute oncology undergraduate teaching at the hospital. The document concludes simulation is a successful method for delivering oncology education that could be applied to other acute oncological emergencies.
Sepsis including Managing Low Risk
Dr Alison Young, Consultant Medical Oncology, Leeds Teaching Hospitals Trust
Dr Andrew Stewart, Haematologist and Lead for Acute Oncology, University Hospitals of the North Midlands
Ceri Stubbs, Clinical Lead, Velindre NHS Trust
Primary Care and Acute Oncology Integration
Dr Sinead Clarke, Macmillan GP Advisor, Clinical Director for Performance, IT, Finance, Cancer and End of Life, South Cheshire and Vale Royal CCGs, Medical Lead for Cheshire end of Life Partnership
Dr Jackie Dominey, GP and Macmillan GP Advisor, Clinical Lead End of Life, Solihull CCG
Palliative Care and Acute Oncology Integration
Dr Catherine O'Doherty, Consultant in Palliative Medicine, Trust Acute Oncology Lead and Lead Cancer Clinician, Basildon and Thurrock University Hospitals NHS Foundation Trust
Karen Andrews, Head of Nursing for Macmillan/Acute Oncology and EOL services, Basildon and Thurrock University Hospitals NHS Foundation Trust
New Services
Cathy Hutchison, Cancer Consultant Nurse, NHS Greater Glasgow & Clyde and Beatson West of Scotland Cancer Centre
Immunuotherapy
Dr Ricky Fraser, Acute Oncology Fellow, South West Wales Cancer Centre
Joanne Upton, Skin Cancer Advanced Nurse Practitioner, The Clatterbridge Cancer Centre
Acute Medicine Skills Part Two
This document summarizes the care of a 73-year-old woman with stage 3 ovarian cancer who presented with worsening shortness of breath. Initial treatment for congestive cardiac failure in the emergency department provided some relief. However, she deteriorated with multi-organ failure and increasing oxygen needs. A discussion was had about her poor prognosis with multi-organ failure in the context of advanced cancer. It was decided that further critical care would not be beneficial and she was made comfortable with best supportive care.
Acute Medicine Skills Part One
Dr Ashling Lillis, National Director's Clinical Fellow Macmillan Support, final year trainee in Acute Oncology
Dr Clare Philliskirk, Trainee in Acute Medicine, West Midlands
Dr Sarbit Clare, Acute Medical Consultant, Sandwell and West Birmingham Hospitals
Sepsis National Approach
The document discusses sepsis and neutropenic sepsis in cancer patients. It provides guidelines from NICE on the management of sepsis and neutropenic sepsis, including the importance of early antibiotic administration. It also discusses outcomes for neutropenic and non-neutropenic sepsis in oncology patients, common pathogens that cause sepsis, and nosocomial infections. Throughout, it emphasizes the importance of early recognition and treatment of sepsis to improve outcomes.
AKI (Acute Kidney Injury)
Dr Tamer Al-Sayed, Acute Physician, The Christie Hospital
Geraldine Campbell, Nurse Clinician, The Christie Hospital
Integration of Acute Medical and Acute Oncology Services
This document discusses the integration of acute medical and acute oncology services. It provides an overview of acute medicine and acute oncology delivery models. It describes the challenges of managing acutely unwell cancer patients and the need for collaboration between acute medicine and oncology specialists. The document also discusses the acute oncology services at The Christie Hospital in Manchester, including the achievements and future directions of the service to provide high quality acute cancer care.
Direct to Oncology Referral
The document describes the development and benefits of an Acute Oncology Service (AOS) pathway for patients presenting with suspected or newly diagnosed cancer. It discusses how the AOS set up direct referral pathways for radiologists to refer patients with suspicious imaging findings. This allows for rapid assessment, diagnosis, and initiation of treatment. The pathway is shown to reduce delays and improve patient experience compared to traditional 2 week wait referrals. Audit data found the pathway effective while also identifying opportunities to better manage non-cancer patients. Overall, the AOS approach aims to provide coordinated, rapid, and symptom-focused care for patients with potential or new cancer diagnoses.
#6 DIRECT GP REFERRALS TO CUP CLINIC: 18 MONTHS ON
The Cancer of Unknown Primary (CUP) clinic in Brighton, UK has accepted direct referrals from general practitioners (GPs) since July 2015 in order to shorten patient diagnosis times. An analysis of data from January to December 2016 showed that 83 patients were seen in the clinic, compared to 56 in 2015. Referrals came most commonly from GPs (36% of cases) and physicians (25% of cases). Direct GP referrals have improved access to expert care and investigations without overwhelming clinic capacity. Most referrals were seen within two weeks. The majority of GP referrals were deemed appropriate after clinic review, with patients receiving a final diagnosis within 3.8 weeks on average.
#11 Delivering acute oncology service remotely using virtual Multidisciplinar...
Eliyaz Ahmed, Macmillan Consultant in Medical Oncology
Clatterbridge Cancer Centre NHS foundation Trust
#2 Development of a traffic light alert system to improve referral processes ...
The document describes the development of a traffic light alert system to improve referral processes for a Macmillan Acute Oncology Service (MAOS). The system was designed to accurately reflect the service's availability to accept referrals, ensure accountability, and expedite discharges. It uses a single web page with color-coded statuses (green, amber, red, black) and corresponding actions to guide referrals. Early results suggest the system improves communication between referrers and MAOS and engagement in expediting discharges. If successful, the alert system may be adopted by other acute assessment areas and oncology services.
#31 Why do patients call acute oncology services?
The Mid Yorkshire Hospitals NHS Trust serves over 550,000 people and delivers almost 15,000 cycles of cancer therapy per year. The trust operates an acute oncology (AO) service during weekday working hours and a 24-hour AO helpline. A recent audit of the AO service found that telephone triage is a main component and that the majority of patients can be managed over the phone without needing to come to the hospital. Appropriate training for staff on triage strategies could help the AO service optimize patient management and prevent unnecessary admissions.
#27 A General Practice Based Audit on Speed of Referral for MRI Spine in Susp...
This audit summarizes a general practice's adherence to NICE guidelines for patients presenting with suspected spinal metastasis. The audit found that of 77 patients who met criteria for suspected spinal metastasis, only 26 were referred for an MRI. None were referred for the recommended whole spine MRI within one week. Potential reasons for non-adherence included a lack of awareness of guidelines by doctors and unclear referral documentation. The audit aims to present results to medical staff to improve guideline adherence and quality of care for patients.
#26 the impact of aos! feedback from the medics!
The survey received 45 responses from medical staff about the Acute Oncology Service (AOS) in Cwm Taf University Health Board. The majority were aware of and had used the AOS, finding the input and advice helpful. Respondents requested more education and training from the AOS team, especially around breaking bad news and managing new cancer diagnoses. Feedback was overall very positive about the accessible and supportive service provided by the AOS.
#23 patients with cancer or suspected cancer presenting
Cathy Hutchison; Dawn Lindsay; Allison Freeman; Elinor Ward
Beatson West of Scotland Cancer Centre - Clinical Governance Support Unit
More from RecoveryPackage (20)
#7 Extending Simulation to the Specialists: Acute Oncology Simulation
#7 Extending Simulation to the Specialists: Acute Oncology Simulation
Integration of Acute Medical and Acute Oncology Services
Integration of Acute Medical and Acute Oncology Services
#6 DIRECT GP REFERRALS TO CUP CLINIC: 18 MONTHS ON
#6 DIRECT GP REFERRALS TO CUP CLINIC: 18 MONTHS ON
#11 Delivering acute oncology service remotely using virtual Multidisciplinar...
#11 Delivering acute oncology service remotely using virtual Multidisciplinar...
#2 Development of a traffic light alert system to improve referral processes ...
#2 Development of a traffic light alert system to improve referral processes ...
#27 A General Practice Based Audit on Speed of Referral for MRI Spine in Susp...
#27 A General Practice Based Audit on Speed of Referral for MRI Spine in Susp...
#23 patients with cancer or suspected cancer presenting
#23 patients with cancer or suspected cancer presenting
Recently uploaded
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Dutch Power Event
“AI – Navigeren naar de toekomst?”
Op 28 mei 2024 bij Info Support.
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...OECD Directorate for Financial and Enterprise Affairs
This presentation by Professor Alex Robson, Deputy Chair of Australia’s Productivity Commission, was made during the discussion “Competition and Regulation in Professions and Occupations” held at the 77th meeting of the OECD Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found at oe.cd/crps.
This presentation was uploaded with the author’s consent.Tom tresser burning issue.pptx My Burning issue
Addressing the status of black home ownership in America. and what actions are taken to impact these trends.
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Dutch Power Event
“AI – Navigeren naar de toekomst?”
Op 28 mei 2024 bij Info Support.
ASONAM2023_presection_slide_track-recommendation.pdf
Presented at the 2023 IEEE/ACM International Conference on
Advances in Social Networks Analysis and Mining.
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
During the May 2024 SSP Conference in Boston, MA, Margie Hlava gave this presentation during the Industry Breakout Session on May 29, 2024.
María Carolina Martínez - eCommerce Day Colombia 2024
María Carolina Martínez - eCommerce Day Colombia 2024
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...Sebastiano Panichella
Announcement of 18th IEEE International Conference on Software Testing, Verification and Validation (ICST) 2025, Napoli, ItalyCompetition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...OECD Directorate for Financial and Enterprise Affairs
This presentation by OECD, OECD Secretariat, was made during the discussion “Competition and Regulation in Professions and Occupations” held at the 77th meeting of the OECD Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found at oe.cd/crps.
This presentation was uploaded with the author’s consent.
XP 2024 presentation: A New Look to Leadership
Presentation slides from XP2024 conference, Bolzano IT. The slides describe a new view to leadership and combines it with anthro-complexity (aka cynefin).
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
• For a full set of 760+ questions. Go to
https://skillcertpro.com/product/databricks-certified-data-engineer-associate-exam-questions/
• SkillCertPro offers detailed explanations to each question which helps to understand the concepts better.
• It is recommended to score above 85% in SkillCertPro exams before attempting a real exam.
• SkillCertPro updates exam questions every 2 weeks.
• You will get life time access and life time free updates
• SkillCertPro assures 100% pass guarantee in first attempt.
Media as a Mind Controlling Strategy In Old and Modern Era
This presentation, created by Syed Faiz ul Hassan, explores the profound influence of media on public perception and behavior. It delves into the evolution of media from oral traditions to modern digital and social media platforms. Key topics include the role of media in information propagation, socialization, crisis awareness, globalization, and education. The presentation also examines media influence through agenda setting, propaganda, and manipulative techniques used by advertisers and marketers. Furthermore, it highlights the impact of surveillance enabled by media technologies on personal behavior and preferences. Through this comprehensive overview, the presentation aims to shed light on how media shapes collective consciousness and public opinion.
International Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in
Software Testing
2024-05-30_meetup_devops_aix-marseille.pdf
Slides de notre meetup DevOps AixMarseille du 30 mai 2024 chez SmarTribune
Sujets: platform engineering / terragrunt / test containers
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
This is a workshop about communication and collaboration. We will experience how we can analyze the reasons for resistance to change (exercise 1) and practice how to improve our conversation style and be more in control and effective in the way we communicate (exercise 2).
This session will use Dave Gray’s Empathy Mapping, Argyris’ Ladder of Inference and The Four Rs from Agile Conversations (Squirrel and Fredrick).
Abstract:
Let’s talk about powerful conversations! We all know how to lead a constructive conversation, right? Then why is it so difficult to have those conversations with people at work, especially those in powerful positions that show resistance to change?
Learning to control and direct conversations takes understanding and practice.
We can combine our innate empathy with our analytical skills to gain a deeper understanding of complex situations at work. Join this session to learn how to prepare for difficult conversations and how to improve our agile conversations in order to be more influential without power. We will use Dave Gray’s Empathy Mapping, Argyris’ Ladder of Inference and The Four Rs from Agile Conversations (Squirrel and Fredrick).
In the session you will experience how preparing and reflecting on your conversation can help you be more influential at work. You will learn how to communicate more effectively with the people needed to achieve positive change. You will leave with a self-revised version of a difficult conversation and a practical model to use when you get back to work.
Come learn more on how to become a real influencer!
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Insight: In a landscape where traditional narrative structures are giving way to fragmented and non-linear forms of storytelling, there lies immense potential for creativity and exploration.
'Collapsing Narratives: Exploring Non-Linearity' is a micro report from Rosie Wells.
Rosie Wells is an Arts & Cultural Strategist uniquely positioned at the intersection of grassroots and mainstream storytelling.
Their work is focused on developing meaningful and lasting connections that can drive social change.
Please download this presentation to enjoy the hyperlinks!
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...Sebastiano Panichella
Doctoral Symposium at the
17th IEEE International Conference on Software Testing, Verification and Validation
(ICST 2024)Recently uploaded (20)
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Presentatie 4. Jochen Cremer - TU Delft 28 mei 2024
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Competition and Regulation in Professions and Occupations – ROBSON – June 202...
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
Presentatie 8. Joost van der Linde & Daniel Anderton - Eliq 28 mei 2024
ASONAM2023_presection_slide_track-recommendation.pdf
ASONAM2023_presection_slide_track-recommendation.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
Supercharge your AI - SSP Industry Breakout Session 2024-v2_1.pdf
María Carolina Martínez - eCommerce Day Colombia 2024
María Carolina Martínez - eCommerce Day Colombia 2024
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Competition and Regulation in Professions and Occupations – OECD – June 2024 ...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...
Media as a Mind Controlling Strategy In Old and Modern Era
Media as a Mind Controlling Strategy In Old and Modern Era
International Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software Testing
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie Wells
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Haematology and Acute Oncology Part One
- 1. Haematology for acute oncologists Dr C Jenkins Aneurin Bevan University Health Board Dr A Stewart University Hospitals of North Midlands
- 2. Introduction • Haematology versus Oncology • Haematological Malignancies • Haematology patients presenting to AOS • Haematology cases
- 3. Haematology diseases • Malignant haematology – Lymphoma – Myeloma – Leukaemia – Myelodysplastic syndromes – Myeloproliferative neoplasms
- 4. Lymphoma
- 10. Myeloma
- 11. Myeloma
- 15. Myeloma
- 16. Myeloma
- 17. Myeloma
- 18. Myeloma
- 19. Myeloma
- 20. Leukaemias Myeloid Lymphoid Acute Chronic Acute Myeloid Leukaemia (AML) Acute Lymphoblastic Leukaemia (ALL) Chronic Myeloid Leukaemia (CML) Chronic Lymphocytic Leukaemia (CLL)
- 21. Normal bone marrow Growth / Proliferation Differentiation Cell Death
- 22. Leukaemia Growth / Proliferation Differentiation Cell Death
- 27. Myelodysplasia Normal neutrophil Dysplastic neutrophil
- 31. Myeloproliferative Neoplasms Chronic myeloid leukaemia
- 32. Myeloproliferative Neoplasms Normal trephine Myelofibrosis
- 33. Haematology diseases • Non-malignant haematology – Autoimmune diseases – Aplastic anaemia – Severe vitamin deficiencies – Thrombosis
- 34. Severe B12 / folate deficiency
- 35. Aneurin Bevan AOS service 9/8/13 – 31/12/16 – Total number of patients seen – 4178 – Number of haematology patients seen - 539
- 36. Aneurin Bevan AOS service 9/8/13 – 31/12/16 – Total number of patients seen – 4178 – Number of haematology patients seen - 539 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20%
- 37. Aneurin Bevan AOS service 9/8/13 – 31/12/16 – Total number of patients seen – 4178 – Number of haematology patients seen - 539 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20%
- 38. Proportions of acute oncology cases New cancer diagnosis Complications of disease Complications of therapy Known cancer – unrelated admission Oncology cases 8% 44% 16% 32% Haematology cases 3% 25% 40% 32%
- 39. New cancer diagnosis • 12 patients with new haem cancers – Lymphoma – Myeloma – Chronic lymphocytic leukaemia
- 40. Complications of the disease Condition Number of patients Pain 29 Bleeding 15 MSCC 14 Ascites 7 Bowel Obstruction 6 Urine Retention 4 Hypercalcaemia 4 Fractures 4 Disease Progression 4 Thromboses 4
- 41. Complications of the treatment Condition Number of patients Neutropaenic sepsis 156 Non-neutopaenic Infections 51 Diarrhoea 20 Nausea / Vomiting 12 Hyperglycaemia 11 Acute Kidney Injury 11